Interview: Lee-Cheng Liu, President & CEO, EirGenix, Taiwan
Dr. Liu, President and CEO of EirGenix, talks about why he sees Taiwan as the ideal market for a CDMO like Eirgenix, why he believes that despite the skepticism, biosimilars…
Address: 6F, No 216-5, Sec. 2, Suiyuan Road, Taichung,Taiwan
Tel: +886 4 2247 3356
For over 15 years, with headquarter in central Taiwan and a branch office in Taipei, and as the pioneer of specialty pharmaceutical distribution locally, Giddi Pharma Co., Ltd. continues to provide excellent services to its global business partners, the local medical community, as well as patients’ advocacy and support groups.
Giddi’s expertise begins with comprehensive & extensive knowledge in various business channels and all distribution models. Its unique one-stop solution, turnkey service capacity has resulted in quick market entry with great efficiency plus cost-saving advantages. From individual named patient import to full scale commercial launch; from product registration, to insurance reimbursement and formulary listing; from international cold chain logistic to pharmacovigilance, Giddi offers comprehensive coverage in each and every aspect of product commercialization.
Giddi’s achievements include several ‘Distributor Excellent Performance Awards’ from Genzyme, 5 times ‘Special Contribution for Supply, Manufacture, Research & Development of Rare Disease Medications’ from Department of Health and Presidential ‘Golden Merchant Award’.
Synergism of innovative leadership with decades of experience from core management team has repeatedly enabled Giddi to formulate adaptive strategies, overcome all challenges and accomplish ultimate goals set by our principals. Each of its 64 employees is also 100% committed to the caring, professional, integrity motto with passion and responsibility.
Giddi’s achievements and successful track records have earned solid reputation and business from global companies like Genzyme, BioMarin, Ipsen and others. With 3 sales teams each dedicated to specific sector for in depth education and relationship cultivation, Giddi is able to maintain double digits growth year after year and becomes the industry leader.
Superior functional and technical expertise coupled with extensive industry knowledge makes Giddi Pharma the ideal choice for your local business partner in Taiwan!
Dr. Liu, President and CEO of EirGenix, talks about why he sees Taiwan as the ideal market for a CDMO like Eirgenix, why he believes that despite the skepticism, biosimilars…
Whaijen Soo, Managing Director of Supra Integration and Incubation Center (Si2C) speaks about Taiwan’s biotech industry, emphasizing the need for risk tolerance and understanding investing rationale in propelling Taiwan’s industry…
Audrey Tseng, Deputy Chairman of PwC Taiwan with PwC Partners Lily Wong and Andy Chang, delve into factors behind the booming pharma and biotech industry in Taiwan, how to prevent…
Dr Yu-Ray Chen, Professor of Surgery at Chang Gung Memorial Hospital discusses the current state of Taiwan’s healthcare system, highlighting the fact that its current condition is unsustainable in the…
Michael Chiang, the Executive President of Panion & BF Biotech speaks about the incredible growth of the company over the past year, what has contributed to this success and where…
James Wang, Country Managing Partner of Ernst & Young Taiwan explains why Taiwan’s DIG (Diversify-Innovative-Globalize) strategy is crucial for the growth of Taiwan’s economy over the next decade, why biotech…
Full service CRO Choice Pharma moved its operations from Europe to Asia in 2008, and since then the company has thrived. The managing director and business director for the company…
A 2006 article in CommonWealth Magazine detailing the genesis of this company reported that TLC had managed to “break out from the typical dilemma of ordinary biotech firms—to either engage…
The president of Pharmaceutical Industry Technology and Development Center (PITDC) considers the company’s need to remain an international competitor and how to achieve it, the gap in new drug development…
General Manager, Chugai Pharma Taiwan and President of International Research-Based Pharmaceutical Manufacturers’ Association (IRPMA), discusses the continuous price cuts that plague the Taiwan market, and how IRPMA is getting involved…
The CEO of ASLAN Pharmaceuticals discusses the fundamental changes that need to occur in the treatment of serious illnesses, the advantages of building a second branch in Taiwan, and the…
The chairman of Taipei Medical University (TMU) discusses the key challenges TMU has faced over the years, how these challenges will continue to affect the future, and what international accreditation…
See our Cookie Privacy Policy Here